GLOBAL UAV ANNOUNCES PROPOSED ACQUISITION OF NEXUS PEPTIDE SCIENCES INC.

VANCOUVER, BRITISH COLUMBIA, July 27, 2026, Global UAV Technologies Ltd. (CSE: UAV.X, OTC:YRLLF, FSE:1OZ) (the "**Company**") is pleased to announce that it is has entered into a letter of intent (the "**LOI**") dated July 27, 2026 with Nexus Peptide Sciences Inc. ("**Nexus**"), a private corporation existing under the laws of British Columbia, pursuant to which the Company would acquire (the "**Transaction**") all of the outstanding securities of Nexus from the securityholders of Nexus (collectively, the "**Nexus Shareholders**").

About Nexus Peptide Sciences Inc.

Nexus Peptide Sciences Inc. is a private biotechnology company, based in Vancouver, British Columbia. Nexus is developing optimized peptide formulations and next-generation delivery systems intended to improve stability, absorption and practical use across metabolic health, recovery and longevity applications.

Peptides are short chains of amino acids that act as native signalling molecules, regulating metabolism, repair, immunity and cognition. Nexus' platform is directed at what the company identifies as the principal constraint on peptide adoption —the molecule itself and the route of delivery, as most peptides degrade rapidly, struggle to cross biological barriers and require injection to remain stable.

Nexus' work spans five areas: molecular optimization (sequence and structural refinement to improve stability, half-life and target selectivity); formulation chemistry (excipient and carrier systems engineered for solubility, shelf-stability and consistent dosing); researching optimal delivery systems (needle-free formats including transdermal patches, oral platforms and absorption-enhanced carriers); quality and verification (manufacturing in approved facilities with batch-level third-party analytical testing for identity, purity and contamination); and regulatory alignment (monitoring of U.S. and international policy to align product positioning with the evolving framework for peptide-based products).

Further information regarding Nexus, its business, its programs and its financial position will be included in the listing statement to be prepared in connection with the Transaction and filed under the Company's profile on SEDAR+.

Summary of the Transaction

The LOI is a non-binding agreement which sets out the principal terms on which the parties have agreed to complete the Transaction. Subject to satisfactory due diligence and successful additional negotiations, the parties intend to enter into a definitive agreement with respect to the Transaction (the "**Definitive Agreement**") on or before August 31, 2026. The Transaction is considered a Fundamental Change pursuant to the policies of the Canadian Securities Exchange (the "**CSE**"), requiring the CSE to review and approve the Transaction. The Transaction is an arm's length transaction.

On completion of the Transaction (the "**Closing**"), the Company has agreed to issue an aggregate of 20,300,000 common shares (each, a "**Share**") in the capital of the Company and 7,000,000 transferable share purchase warrants (each, a "**Warrant**") of the Company to the Nexus Shareholders on a pro-rata basis. Each Warrant is exercisable into one additional Share (each, a "**Warrant Share**") at an exercise price of $0.10 per Warrant Share for a period of two years following the Closing in consideration for the acquisition of all of the securities of Nexus. Immediately before the Closing, Global UAV has agreed that there will be no more than 33,000,000 Shares and 17,000,000 share purchase warrants issued and outstanding, with such warrants to have an exercise price of $0.10 per Share. At the time of Closing, Nexus will become a wholly-owned subsidiary of the Company. If issued, the Shares and Warrants may be subject to certain restrictions on transfer pursuant to the requirements of applicable law. The Company anticipates that there will be a finder's fee in connection with the Transaction comprised of $100,000 in cash and 1,000,000 in Shares.

The Transaction will be completed pursuant to available exemptions under applicable legislation. The Company may pay a finder's fee in connection with the Transaction.

Concurrent Financing

On or before the Closing of the Transaction, the Company intends on completing an equity financing of a minimum of $3,000,000 and a maximum of $5,000,000.

Board and Management

On Closing of the Transaction, the board of directors of the combined company (the "**Resulting Issuer**") will consist of five (5) directors — three (3) nominees of Nexus (Dr. Patrick Gunning, Dr. Mark Lindsay and Dr. Mona Ezzat-Velinov) and two (2) continuing directors of the Company (Ron Schmitz and Tim Ko). The Company anticipates that it on Closing Chris Cherry will be appointed as Chief Financial Officer. Additional information on the proposed directors, officers and Insiders (as defined in the policies of the CSE) of the Resulting Issuer will be included in subsequent press releases in connection with the Transaction.

Dr. Patrick Gunning — Proposed Director and Chief Scientific Officer

Dr. Gunning is a Professor of Molecular Therapeutics at the University of Glasgow and a Professor of Chemistry at the University of Toronto, and was previously a Canada Research Chair in Medicinal Chemistry and founder and inaugural Director of the Centre for Medicinal Chemistry. He earned his Ph.D. from the University of Glasgow and completed postdoctoral studies at Yale University. He has authored over 140 research publications and is a Fellow of the Royal Society of Chemistry; his recognitions include the Boehringer Ingelheim Young

Investigator Award, the RSC MedChemComm Emerging Investigator Lectureship and Canada's Top 40 Under 40. Dr. Gunning has co-founded multiple biotechnology companies, including Janpix Inc., Centessa Pharmaceuticals (Nasdaq: CNTA), Dunad Therapeutics, Dalriada Drug Discovery, HDAX Therapeutics and Carnyx Therapeutics.

Dr. Mark Lindsay – Proposed Director

Dr. Lindsay is a Doctor of Chiropractic and a graduate of Palmer Chiropractic College, with 35 years of experience working with elite athletes, including Super Bowl, Stanley Cup and MLB championship teams and Olympic and world champions. He is a Diplomate of the American Chiropractic Neurology Board and a member of the Ontario and Colorado Chiropractic Associations, and is a Ph.D. candidate in the Neuroscience Program at Queen's University. He has completed over 3,000 hours of graduate study in neurology through the Carrick Institute for Graduate Studies, is the author of Fascia: Clinical Applications for Health and Human Performance and ten research publications, and serves as a Research Fellow at the Steadman Philippon Research Institute in Vail, Colorado. He is a co-founder of Carnyx Therapeutics, Kelvin Therapeutics and Entourage AI.

Dr. Mona Ezzat-Velinov – Proposed Director

Dr. Ezzat-Velinov is a board-certified family physician with more than 25 years of clinical experience specializing in integrative and functional medicine, and works in longevity medicine. She has provided expertise to healthcare and technology organizations including Apple, Facebook, One Medical, Human Longevity and Fountain Life, is a frequent conference speaker including at the Buck Institute, and has authored published chapters on integrative wellness and women's longevity. She is a member of the American Academy of Family Physicians, the Institute for Functional Medicine and the Mast Cell Academy.

Chris Cherry – Proposed Chief Financial Officer

Mr. Cherry has over 20 years of corporate accounting and audit experience and has held senior positions with several public mining companies, including director, chief financial officer and secretary. He is a CPA, having obtained the Chartered Accountant designation in 2009 and the Certified General Accountant designation in 2004. He previously held positions with KPMG and Davidson & Co. LLP in Vancouver, auditing junior public companies.

Ron Schmitz – Continuing Director, President and Chief Executive Officer

Mr. Schmitz has been a director, chief executive officer and chief financial officer of numerous public companies since 1997, and is an active participant in the junior markets. Mr. Schmitz is also the president of ASI Accounting Services Inc., which has provided administrative, accounting and office services to public and private companies since 1995.

Tim Ko – Continuing Director

Mr. Ko is an entrepreneur who has successfully founded and operated businesses in technology and biotech. He has served at both the executive and board level, and has overseen the successful financing, acquisition and operations of businesses in his time within the Canadian public markets.

Completion of the Transaction remains subject to a number of conditions, including satisfactory due diligence, entry into the Definitive Agreement, completion of audited financial statements for Nexus, the receipt of all requisite approvals required to consummate the Transaction, and other conditions customary for transactions of this nature. The LOI includes a completion deadline of August 31, 2026. The parties will endeavor to complete the Transaction as soon as practicable and intends to complete the Transaction prior to the completion deadline. There can be no assurance that the Transaction will be completed as proposed or at all.

Completion of the Transaction is subject to a number of conditions, including acceptance of the CSE. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Act"), or any state securities laws and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.

On Behalf of the Board of Directors

"Ron Schmitz"

Ron Schmitz
Director, President and CEO
Telephone: (604) 685-7450

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future. Although the Company believes that such statements are reasonable and reflect expectations of future developments and other factors which management believes to be reasonable and relevant, the Company can give no assurance that such expectations will prove to be correct. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that the requisite approvals for the completion of the Transaction will be obtained; that the Company or Nexus, as applicable, will be able to satisfy any or all closing conditions necessary for the completion of the Transaction; and that the Company and Nexus will enter into the Definitive Agreement and close the Transaction by the proposed dates. Forward-looking statements in this press release include, but are not limited to, statements regarding: the completion of the Transaction; the structure and timing of the Transaction, the completion, size, and use of proceeds of the Financing; anticipated timing of any changes to management roles; anticipated changes to the board of directors and management of the Company; the appointment of new directors; and the satisfaction of closing conditions, regulatory approvals, and other approvals required to consummate the Transaction. Factors that could cause actual results to differ materially from those contemplated by *the forward-looking statements include, among others: the failure to complete the Transaction or the Financing on the terms described or at all; the inability to satisfy closing conditions or obtain required regulatory, exchange, or shareholder approvals; changes in market conditions; the availability of financing; risks related to the issuance, conversion, and dilution effects of equity securities; risks related to the supplement market; execution risks associated with integrating Nexus' business following the Closing; changes in applicable laws or regulations; competitive pressures; and general economic and business conditions. Other factors may also adversely affect the future results or performance of the Company, including the risks and uncertainties which are more fully described in the Company's annual and quarterly management's discussion and analysis and in other filings made by the Company with Canadian securities regulatory authorities under the Company's SEDAR+ profile. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The Company does not undertake any obligation to update such forward-looking information whether because of new information, future events or otherwise, except as expressly required by applicable law.*